FDA guidance
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug…
FDA guidance · Final · issued Jun 16, 2025
Key facts
| Title | ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions |
|---|---|
| Status | Final |
| Issue date | Jun 16, 2025 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research, Office of Pharmaceutical Quality |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2017-D-3101 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents